Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma | Region
PRINCETON, N.J.--(BUSINESS WIRE)--May 15, 2024--
Source: eagletribune.com
Page 4 - Risk Evaluation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Risk Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Risk Evaluation Today - Breaking & Trending Today
FDA Broadens Breyanzi's Follicular Lymphoma Indication
The overall response rate to the CAR T therapy was 95.7% in phase 2 testing.
Source: medscape.com
FDA Grants Accelerated Approval for Liso-Cel for R/R Follicular Lymphoma
FDA has given accelerated approval for lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed or refractory (R/R) follicular lymphoma.
Source: ajmc.com
Dr Dahiya on the FDA Approval of Liso-Cel for Relapsed/Refractory Follicular Lymphoma
Saurabh Dahiya, MD, FACP, discusses the FDA approval of lisocabtagene maraleucel for patients with relapsed/refractory follicular lymphoma.
Source: onclive.com
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® $25.6 million for EMPAVELI® Anticipates CHMP opinion for pegcetacoplan...
Source: marketscreener.com